Keynote presentation 2: BPS Lecturer
Monday, December 2, 2024 |
8:00 AM - 8:50 AM |
Goldfields Theatre |
Details
Medcines are one of the most common health care interventions. However, following introduction of medicines or therapeutics into clinical practice we are not always able to understand if they are used as intended or if they are having the intended effects. One way to be able to do this is by ensuring medicines data are linked to health outcome data so as to enable us to understand the clinical and cost-effectivenss better. Until recently, this was not possible in the UK, however we now show what can begin to be understood if this were possible. In the same way we can use large scale data to use medicines better we can use the growing fields of multi-omics (including genomics, proteomics, metabolomics) to make medicines better. By embedding research into routine clinical practice and using both clinical data linked to -omic data we can begin to understand the biological and patholphysioloy of disease better and use these measures and statistal method to discovery repurposing oppurtunities as well as discovery of drug targets.
Speaker
Prof Reecha Sofat
University of Liverpool
Making and Using Medicines better using a data science approach
Biography
Professor Reecha Sofat is Breckenrdige Chair in Clinical Pharmacology and Therapeutics at the University of Liverpool and an NIHR Research Professor. She is Vice President, Clinical at the British Pharmacological Society, Associate Director at the British Heart Foundation Data Science Centre which is led by Health Data Research UK. She has also recently taken up Chair of the Board at the Professional Record Standards Body.
Her activities are linked to her research, the golden thread being data sciences. Her research interests are in making and using medicines better using a data science approach. In using medicines better she leverage electronic health record data linked to health outcome data to understand how and where medicines are used, including strategies to inform medicines policy decisions, cost-effectiveness as well as methods such as causal inference to determine medicines repurposing opportunities. Making medicines better is about leveraging large scale biological data such as genomics and multi-omics to understand the molecular underpinnings of complex disease better so as to begin to unmet need and use these methods to better identify drug targets or therapeutic opportunities.
Chair
Bridin Murnion
St. Vincent's Hospital Sydney